ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) today announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed to kill cancer cells by preventing cell mitosis.
ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) today announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed to kill cancer cells by preventing cell mitosis.
